A Look Back at Halozyme's Volatile but Rewarding 2013
As 2013 draws to a close, let’s take a look back at Halozyme’s volatile performance throughout the year and review its key collaborations with ViroPharma (Shire), Roche, Baxter, and Pfizer.
Eli Lilly Struggles for Pipeline Success
Edivoxetine failure dampens Lilly's R&D efforts
Morning Dow Report: Pfizer, Coca-Cola Stumble as Goldman and JPMorgan Celebrate
The Dow was little changed this morning, with industry-specific positive news sending Goldman Sachs and JPMorgan Chase higher even as defensive stocks Pfizer and Coca-Cola fell. Find out what moved the Dow.
3 Budding Drug Superstars in This Big Pharma's Future
Can Bristol-Myers Squibb keep its amazing growth in 2013 going strong in the future? It'll rely on ballyhooed drugs like these to discover its future growth.